Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BCX4161 in Healthy Volunteers
NCT02125162Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avoralstat in hereditary angioedema (HAE) (3 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Plasma pharmacokinetics to assess the relative bioavailability of BCX4161 soft gelatin capsules to hard gelatin capsules at 24 hours. Started Apr 2014; status: completed.
02
Drugs
avoralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02125162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125162.